Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I study with repeated doses of the Multiple Ascending Dose of RMC-035

Next Previous
Trial Profile

A Phase I study with repeated doses of the Multiple Ascending Dose of RMC-035

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 31 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RMC 035 (Primary)
  • Indications Acute kidney injury; Radiation injuries
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 31 Aug 2021 Status has been changed to completed as per guard therapeutics pipeline
    • 14 Nov 2018 New trial record
    • 09 Nov 2018 According to an A1M Pharma AB media release, the Swedish Medicines Agency has given permission to initiate the Phase I clinical trial of ROSgard. Single Ascending Dose part is expected to start in the first quarter of 2019 and Multiple Ascending Dose part in the second half of 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top